FAVORITO, VALENTINA
 Distribuzione geografica
Continente #
AS - Asia 345
EU - Europa 152
NA - Nord America 137
SA - Sud America 19
AF - Africa 7
Totale 660
Nazione #
US - Stati Uniti d'America 134
VN - Vietnam 105
CN - Cina 91
SG - Singapore 87
IT - Italia 70
HK - Hong Kong 31
NL - Olanda 30
BR - Brasile 16
DE - Germania 14
IN - India 13
KR - Corea 10
FI - Finlandia 9
FR - Francia 6
GB - Regno Unito 6
CH - Svizzera 3
IQ - Iraq 3
RU - Federazione Russa 3
BE - Belgio 2
CI - Costa d'Avorio 2
JP - Giappone 2
KE - Kenya 2
MX - Messico 2
PL - Polonia 2
SC - Seychelles 2
AE - Emirati Arabi Uniti 1
AR - Argentina 1
AT - Austria 1
BA - Bosnia-Erzegovina 1
BD - Bangladesh 1
CA - Canada 1
DZ - Algeria 1
EC - Ecuador 1
EE - Estonia 1
GR - Grecia 1
IE - Irlanda 1
IL - Israele 1
LT - Lituania 1
PE - Perù 1
SE - Svezia 1
Totale 660
Città #
Singapore 58
Ashburn 40
Dallas 34
Hefei 33
Ho Chi Minh City 30
Hong Kong 30
Hanoi 26
Bologna 22
Beijing 12
Santa Clara 11
Seoul 10
Los Angeles 8
Boardman 7
Milan 6
Modena 6
Munich 6
Visakhapatnam 5
Amsterdam 4
Da Nang 4
Ha Long 4
Helsinki 4
Pescara 4
Bengaluru 3
Buffalo 3
Bắc Ninh 3
Changsha 3
Frankfurt am Main 3
Haiphong 3
Luco dei Marsi 3
Mumbai 3
New York 3
Quận Một 3
Quận Phú Nhuận 3
Redondo Beach 3
Shanghai 3
Turku 3
Abidjan 2
Biên Hòa 2
Brussels 2
Bắc Giang 2
Can Tho 2
Chongqing 2
Denver 2
Falkenstein 2
Hải Dương 2
Nanyang 2
Ninh Bình 2
Novara 2
Poplar 2
Qingdao 2
Quảng Ninh 2
Rio de Janeiro 2
Salerno 2
San Francisco 2
Taurianova 2
Tokyo 2
Turin 2
Tân An 2
Vinh 2
Warsaw 2
Zurich 2
Algiers 1
Almenno San Bartolomeo 1
Amparo 1
Barbacena 1
Bexley 1
Boston 1
Boydton 1
Bình An 1
Campinas 1
Caçapava 1
Cesena 1
Changchun 1
Chaohu 1
Chennai 1
Chimbote 1
Córdoba 1
Dublin 1
Elk Grove Village 1
Erba 1
Florianópolis 1
García 1
Goiânia 1
Gravataí 1
Greenwich 1
Guangzhou 1
Guayaquil 1
Hyderabad 1
Jacarezinho 1
Jaguarão 1
Kai Yi Wan 1
Kampong Loyang 1
Kirkuk 1
Kunming 1
Lages 1
Lang Son 1
Lappeenranta 1
Manchester 1
Mauá 1
Maysan 1
Totale 495
Nome #
STK11 mutations correlate with poor prognosis for advanced NSCLC treated with first-line immunotherapy or chemo-immunotherapy according to KRAS, TP53, KEAP1, and SMARCA4 status 133
Lung adenocarcinomas with mucinous histology: clinical, genomic, and immune microenvironment characterization and outcomes to immunotherapy-based treatments and KRASG12C inhibitors 133
Development and validation of a new tool to estimate early mortality in patients with advanced cancer treated with immunotherapy 111
Early monitoring of plasma KRAS G12C with digital PCR predicts antitumor response to immunotherapy or sotorasib in advanced NSCLC: A brief report 91
Resistance to KRAS G12C Inhibition in Non-small Cell Lung Cancer 73
First-Generation Epidermal Growth Factor Receptor Inhibitors Plus Antiangiogenic Drugs Versus Third-Generation Epidermal Growth Factor Receptor Inhibitors in Advanced Non-Small-Cell Lung Cancer: A Meta-Analysis 68
Non-small cell lung cancer: an update on emerging EGFR-targeted therapies 63
Totale 672
Categoria #
all - tutte 1.479
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 1.479


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2023/20247 0 0 0 0 0 0 0 1 2 0 0 4
2024/2025261 1 8 5 18 26 12 25 19 6 41 31 69
2025/2026404 141 73 64 70 37 19 0 0 0 0 0 0
Totale 672